---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-027086"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T21:10:28.807699+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Oncocyte gets Nasdaq notice of prior noncompliance and regained compliance after director death

## Summary
- Director Alfred D. Kingsley died April 25, 2024, causing noncompliance with Nasdaq independent board and audit committee rules.
- Effective July 1, 2024, director Andrew Arno was deemed independent and appointed to the audit committee, restoring compliance.
- Nasdaq Staff confirmed compliance on July 8, 2024; no further action required.
- The company had previously disclosed the independence determination in a Form 8-K filed July 5, 2024.

## SEC filing metadata
- accession: 0001493152-24-027086
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224027086/0001493152-24-027086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224027086/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-027086
- JSON: https://secwatch.observer/filing/0001493152-24-027086.json
- Plain text: https://secwatch.observer/filing/0001493152-24-027086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.